Prevalence of Contact Allergy to Neomycin in Dermatitis Patients: A Systematic Review and Meta‐Analysis
Contact Dermatitis · 2025
DOI: 10.1111/cod.14784 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Contact Dermatitis, 2025. Verfasst von Mikkel Bak Jensen und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Allergy Research Centre, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Dermatitis, Allergic Contact, Neomycin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Danish Environmental Protection Agency under the Ministry of Environment of Denmark.
Abstract (Originalsprache)
Neomycin, an aminoglycoside antibiotic frequently employed in topical formulations, is a recognised allergen that is part of many baseline series and can cause contact allergy (CA) in both adults and children. It is an allergen of interest as it has a widespread use in over‐the‐counter and prescription products globally, but geographical variations may exist. This study aimed to establish prevalence estimates of CA to neomycin in dermatitis patients and to investigate potential geographical variations. Three databases (PubMed, Embase, and Web of Science) were screened, revealing 70 included studies comprising 456 372 adults and 17 720 children who underwent patch testing. The pooled prevalence of CA to neomycin was found to be 3.2% (95% confidence interval [CI]: 2.6%–3.8%) in adults and 4.3% (95% CI: 2.65%–6.3%) in children. The highest prevalences were observed in North America (adults: 6.4%; children: 8.1%) and South Asia (adults: 4.9%), while Europe showed lower rates (adults: 2.5%; children: 0.8%). Studies after the year 2000 indicated a prevalence of 2.1% in adults and 5.1% in children across geographical regions. These findings highlight a public health concern, particularly in regions with high prevalence rates. The study underscores the need for more restrictive use of neomycin to reduce the incidence of neomycin‐induced CA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Allergy Research Centre, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark.
- Institute of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark.
- Department of Dermatology and Allergy, Herlev and Gentofte - Copenhagen University Hospital, Copenhagen, Denmark.
ORCID-Profile: Mikkel Bak Jensen, Daniel Isufi, Christoffer Kursawe Larsen, Jakob Ferløv Baselius Schwensen, Farzad Alinaghi, Jeanne Duus Johansen
Förderung
- The Danish Environmental Protection Agency under the Ministry of Environment of Denmark
Zitieren
APA
Jensen, M. B., Isufi, D., Larsen, C. K., Schwensen, J. F. B., Alinaghi, F., & Johansen, J. D. (2025). Prevalence of Contact Allergy to Neomycin in Dermatitis Patients: A Systematic Review and Meta‐Analysis. Contact Dermatitis. https://doi.org/10.1111/cod.14784
Vancouver
Jensen MB, Isufi D, Larsen CK, Schwensen JFB, Alinaghi F, Johansen JD. Prevalence of Contact Allergy to Neomycin in Dermatitis Patients: A Systematic Review and Meta‐Analysis. Contact Dermatitis. 2025. doi:10.1111/cod.14784
BibTeX
@article{Jensen2025,
author = {Jensen, Mikkel Bak and Isufi, Daniel and Larsen, Christoffer Kursawe and Schwensen, Jakob Ferløv Baselius and Alinaghi, Farzad and Johansen, Jeanne Duus},
title = {Prevalence of Contact Allergy to Neomycin in Dermatitis Patients: A Systematic Review and Meta‐Analysis},
journal = {Contact Dermatitis},
year = {2025},
doi = {10.1111/cod.14784}
}
EUVIMED